First Time Loading...

Clearside Biomedical Inc
NASDAQ:CLSD

Watchlist Manager
Clearside Biomedical Inc Logo
Clearside Biomedical Inc
NASDAQ:CLSD
Watchlist
Price: 1.31 USD -0.76% Market Closed
Updated: Apr 20, 2024

Intrinsic Value

CLSD's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

Clearside Biomedical, Inc. is a biopharmaceutical company, which engages in the development of drug therapies to treat blinding diseases of the eye. [ Read More ]

The intrinsic value of one CLSD stock under the Base Case scenario is 0.74 USD. Compared to the current market price of 1.31 USD, Clearside Biomedical Inc is Overvalued by 44%.

Key Points:
CLSD Intrinsic Value
Base Case
0.74 USD
Overvaluation 44%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Clearside Biomedical Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling CLSD stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
Clearside Biomedical Inc

Provide an overview of the primary business activities
of Clearside Biomedical Inc.

What unique competitive advantages
does Clearside Biomedical Inc hold over its rivals?

What risks and challenges
does Clearside Biomedical Inc face in the near future?

Has there been any significant insider trading activity
in Clearside Biomedical Inc recently?

Summarize the latest earnings call
of Clearside Biomedical Inc.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Clearside Biomedical Inc.

Provide P/S
for Clearside Biomedical Inc.

Provide P/E
for Clearside Biomedical Inc.

Provide P/OCF
for Clearside Biomedical Inc.

Provide P/FCFE
for Clearside Biomedical Inc.

Provide P/B
for Clearside Biomedical Inc.

Provide EV/S
for Clearside Biomedical Inc.

Provide EV/GP
for Clearside Biomedical Inc.

Provide EV/EBITDA
for Clearside Biomedical Inc.

Provide EV/EBIT
for Clearside Biomedical Inc.

Provide EV/OCF
for Clearside Biomedical Inc.

Provide EV/FCFF
for Clearside Biomedical Inc.

Provide EV/IC
for Clearside Biomedical Inc.

Show me price targets
for Clearside Biomedical Inc made by professional analysts.

What are the Revenue projections
for Clearside Biomedical Inc?

How accurate were the past Revenue estimates
for Clearside Biomedical Inc?

What are the Net Income projections
for Clearside Biomedical Inc?

How accurate were the past Net Income estimates
for Clearside Biomedical Inc?

What are the EPS projections
for Clearside Biomedical Inc?

How accurate were the past EPS estimates
for Clearside Biomedical Inc?

What are the EBIT projections
for Clearside Biomedical Inc?

How accurate were the past EBIT estimates
for Clearside Biomedical Inc?

Compare the revenue forecasts
for Clearside Biomedical Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Clearside Biomedical Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Clearside Biomedical Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Clearside Biomedical Inc compared to its peers.

Compare the P/E ratios
of Clearside Biomedical Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Clearside Biomedical Inc with its peers.

Analyze the financial leverage
of Clearside Biomedical Inc compared to its main competitors.

Show all profitability ratios
for Clearside Biomedical Inc.

Provide ROE
for Clearside Biomedical Inc.

Provide ROA
for Clearside Biomedical Inc.

Provide ROIC
for Clearside Biomedical Inc.

Provide ROCE
for Clearside Biomedical Inc.

Provide Gross Margin
for Clearside Biomedical Inc.

Provide Operating Margin
for Clearside Biomedical Inc.

Provide Net Margin
for Clearside Biomedical Inc.

Provide FCF Margin
for Clearside Biomedical Inc.

Show all solvency ratios
for Clearside Biomedical Inc.

Provide D/E Ratio
for Clearside Biomedical Inc.

Provide D/A Ratio
for Clearside Biomedical Inc.

Provide Interest Coverage Ratio
for Clearside Biomedical Inc.

Provide Altman Z-Score Ratio
for Clearside Biomedical Inc.

Provide Quick Ratio
for Clearside Biomedical Inc.

Provide Current Ratio
for Clearside Biomedical Inc.

Provide Cash Ratio
for Clearside Biomedical Inc.

What is the historical Revenue growth
over the last 5 years for Clearside Biomedical Inc?

What is the historical Net Income growth
over the last 5 years for Clearside Biomedical Inc?

What is the current Free Cash Flow
of Clearside Biomedical Inc?

Financials

Balance Sheet Decomposition
Clearside Biomedical Inc

Current Assets 30.1m
Cash & Short-Term Investments 28.9m
Receivables 170k
Other Current Assets 1m
Non-Current Assets 3.9m
PP&E 3.9m
Other Non-Current Assets 30k
Current Liabilities 6.8m
Accounts Payable 2.2m
Accrued Liabilities 4.5m
Other Current Liabilities 75k
Non-Current Liabilities 43.1m
Other Non-Current Liabilities 43.1m
Efficiency

Earnings Waterfall
Clearside Biomedical Inc

Revenue
8.2m USD
Cost of Revenue
-355k USD
Gross Profit
7.9m USD
Operating Expenses
-32.7m USD
Operating Income
-24.8m USD
Other Expenses
-7.6m USD
Net Income
-32.5m USD

Free Cash Flow Analysis
Clearside Biomedical Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
What is Free Cash Flow?
Fundamental Scores

CLSD Profitability Score
Profitability Due Diligence

Clearside Biomedical Inc's profitability score is 35/100. The higher the profitability score, the more profitable the company is.

Exceptional ROE
Exceptional Revenue Growth Forecast
Exceptional 1-Year Revenue Growth
ROE is Increasing
35/100
Profitability
Score

Clearside Biomedical Inc's profitability score is 35/100. The higher the profitability score, the more profitable the company is.

CLSD Solvency Score
Solvency Due Diligence

Clearside Biomedical Inc's solvency score is 51/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Low D/E
Long-Term Solvency
Low Altman Z-Score
51/100
Solvency
Score

Clearside Biomedical Inc's solvency score is 51/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

CLSD Price Targets Summary
Clearside Biomedical Inc

Wall Street analysts forecast CLSD stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for CLSD is 5.61 USD with a low forecast of 4.04 USD and a high forecast of 8.4 USD.

Lowest
Price Target
4.04 USD
208% Upside
Average
Price Target
5.61 USD
328% Upside
Highest
Price Target
8.4 USD
541% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

CLSD Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

CLSD Price
Clearside Biomedical Inc

1M 1M
-20%
6M 6M
+60%
1Y 1Y
+17%
3Y 3Y
-52%
5Y 5Y
+5%
10Y 10Y
-82%
Annual Price Range
1.31
52w Low
0.68
52w High
2.02
Price Metrics
Average Annual Return 13.25%
Standard Deviation of Annual Returns 58.24%
Max Drawdown -91%
Shares Statistics
Market Capitalization 97.9m USD
Shares Outstanding 74 720 000
Percentage of Shares Shorted 0.32%

CLSD Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

Clearside Biomedical Inc Logo
Clearside Biomedical Inc

Country

United States of America

Industry

Pharmaceuticals

Market Cap

97.9m USD

Dividend Yield

0%

Description

Clearside Biomedical, Inc. is a biopharmaceutical company, which engages in the development of drug therapies to treat blinding diseases of the eye. The company is headquartered in Alpharetta, Georgia and currently employs 34 full-time employees. The company went IPO on 2016-06-02. The firm is focused on developing and delivering therapies to the back of the eye diseases through the suprachoroidal space (SCS). Its SCS injection platform utilizing its SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted delivery of a variety of therapies to the macula, retina or choroid to preserve and improve vision in patients with sight-threatening eye diseases. The company is focused on developing its own pipeline of small molecule product candidates for administration via its SCS Microinjector, and it also partners with companies developing other ophthalmic therapeutics to be administered using its SCS injection platform. Its lead product candidate, XIPERE, is a preservative-free suspension of the corticosteroid triamcinolone acetonide (TA), formulated for administration through suprachoroidal injection. Its pipeline includes CLS-AX, CLS-301 and Gene Therapy.

Contact

GEORGIA
Alpharetta
900 N Point Pkwy Ste 200
+16782703631.0
http://clearsidebio.com/

IPO

2016-06-02

Employees

34

Officers

President, CEO & Director
Dr. George M. Lasezkay J.D., Pharm.D., Pharma.D.
Chief Financial Officer
Mr. Charles A. Deignan
Chairman of Scientific Advisory Board
Dr. Thomas A. Ciulla M.B.A., M.D.
Head of Investor Relations
Ms. Jenny R. Kobin
Vice President of Corporate Development
Mr. Rick McElheny
Senior Vice President of Engineering & Manufacturing
Mr. Rafael V. Andino
Show More
Chief Clinical Officer
Ms. Susan L. Coultas Ph.D.
Chief Medical Officer
Dr. Ngai Hang Chong M.B.A., M.D.
Secretary
Mr. Leslie B. Zacks
Show Less

See Also

Discover More
What is the Intrinsic Value of one CLSD stock?

The intrinsic value of one CLSD stock under the Base Case scenario is 0.74 USD.

Is CLSD stock undervalued or overvalued?

Compared to the current market price of 1.31 USD, Clearside Biomedical Inc is Overvalued by 44%.